Eur Heart J 44(39):40434140
According to NICE guidance, GLP-1 receptor agonists are recommended for specific patient groups with type 2 diabetes (NG28) and, in some formulations like Wegovy (semaglutide 2.4mg) and Saxenda (liraglutide 3mg), for weight management in adults with obesity or overweight with weight-related comorbidities
It does this partly by facilitating the localization of key metabolic enzymes within mitochondria, supporting their structural integrity and protecting against oxidative damage to mitochondrial DNA [2]
Use DEXA to see how fat mass, lean mass, and visceral fat change as you lose weight
But the shortage has since ended, and the FDA ordered compounders to stop manufacturing mass-compounded GLP-1 drugs in early 2025
Not willy-nilly, not just like, Hey, let's just give GLP one to everyone